Skip to main content
NHS National Services Scotland Home
FOI release

FOI – 2025-000256 Coagulation Factors (HTML)

Published on 11 September 2025

Date received – 15 August 2025 | Date responded – 11 September 2025

Response

We have now completed the search of our records and can provide you with the following information:

1. How many patients did you treat with Bypassing agents (BPA)/Hemlibra inhibitor in (January, February, March, April, May and June 2025)?

a) With BPA/Hemlibra Inhibitor?

Under Section 17 of the Freedom of Information Scotland Act, 2002 (FOISA) an organisation does not have to provide that information if it does not hold it. NHS National Services Scotland (NSS) does not hold the data for the exact number of patients treated with bypassing agents (BPAs).

Please find attached Appendix 1 – Patient Numbers. This shows the number of unique patient IDs per month requested, including the number of unique patient IDs across the entire time period requested, that are subscribed to the delivery service and received BPAs under NP30919 - Homecare Deliveries of Clotting Medicines. Please note, the figures provided are taken from the unique patient IDs and as such, this does not necessarily represent the exact number of patients. Under Section 38(1)(b) of the FOISA, NSS has redacted information where the number of patients is five or fewer. This redaction has been applied to prevent the potential identification of individuals, in accordance with the data protection principles outlined in the UK General Data Protection Regulation (UK GDPR) and the Data Protection Act 2018. The decision is also consistent with the Caldicott Principles.

2. Please fill in the BPA/Hemlibra products utilized in January, February, March, April, May and June 2025)?

Under section 17 of FOISA, an organization does not have to provide that information if it does not hold it. NSS does not hold this level of information and as such, are unable to fill in the table you have provided asking for breakdowns by indication.

Please find attached Appendix 2 – Usage of Medicines. This shows the volume of BPA/Hemlibra products that were delivered to patients during the months requested under NP30919 - Homecare Deliveries of Clotting Medicines. Although the data NSS holds shows the volume of BPA/Hemlibra products delivered to patients, NSS cannot confirm that the products were used. We recommend contacting the individual Health Boards (HBs) using the details provided below to obtain further information.

Under Section 38(1)(b) of the Freedom of Information (Scotland) Act 2002 (FOISA), NSS has redacted information relating to the usage of certain products, specifically NovoSeven, where the associated patient numbers are five or fewer. This decision has been made to prevent the potential identification of individuals, in accordance with the data protection principles set out in the UK GDPR and the Data Protection Act 2018. The redaction is also consistent with the Caldicott Principles.

3. How many minor and major surgeries did your BPA patients have in January, February, March, April, May and June 2025)?

Under section 17 of FOISA, an organization does not have to provide that information if it does not hold it. NSS does not hold any information relating to the number of minor or major surgeries that BPA patients have undergone in the months requested as NSS does not record this level of information. We recommend contacting the individual HBs using the details provided below to obtain further information.

4. How many minor and major surgeries did your BPA/Hemlibra inhibitor patients have in January, February, March, April, May and June 2025)?

Under section 17 of FOISA, an organization does not have to provide that information if it does not hold it. NSS does not hold any information relating to the number of minor or major surgeries that BPA/Hemlibra patients have undergone in the months requested as NSS does not record this level of information. We recommend contacting the individual HBs using the details provided below to obtain further information.

5. How many breakthrough bleeds did your Hemlibra Inhibitor patients have, and what brand were they treated with?

Under section 17 of FOISA, an organization does not have to provide that information if it does not hold it. NSS does not hold any information relating to the number of breakthrough bleeds that Hemlibra Inhibitor patients had or the brand that they were treated with as NSS does not record this level of information. We recommend contacting the individual HBs using the details provided below to obtain further information.

6. Were there any changes in the total number of acute bleeds treated with factor in Q2’25 (April-June 2025) compared to Q1’25 (Jan–Mar 2025)? If yes, please specify whether there was an increase, decrease, or no change, and provide actual numbers if available.

Under section 17 of FOISA, an organization does not have to provide that information if it does not hold it. NSS does not hold any information relating to the number of acute bleeds treated with factors in the months you have requested as NSS does not record this level of information. We recommend contacting the individual HBs using the details provided below to obtain further information.

7. Was there any change in the number of elective surgeries using factors in Q2’25 compared to Q1’25? Please specify the number of surgeries in both quarters and clarify if there was an increase, decrease, or no change.

Under section 17 of FOISA, an organization does not have to provide that information if it does not hold it. NSS does not hold any information relating to the change, if any, in the number of elective surgeries using factors in the months requested as NSS does not record this level of information. We recommend contacting the individual HBs using the details provided below to obtain further information.

8. Have any BPA patients switched products between January 1st through June 2025? What were the reasons for the switches?

Under section 17 of FOISA, an organization does not have to provide that information if it does not hold it. NSS does not hold any information relating to whether BPA patients have switched products in the months you have requested as NSS does not record this level of information. We recommend contacting the individual HBs using the details provided below to obtain further information:

9. What is the total number of patients treated with NovoSeven at NHS Scotland for each month (January–June 2025)?

Under Section 38(1)(b) of the Freedom of Information (Scotland) Act 2002 (FOISA), NSS has redacted information relating to the usage of certain products, specifically NovoSeven, where the associated patient numbers are five or fewer. This decision has been made to prevent the potential identification of individuals, in accordance with the data protection principles set out in the UK GDPR and the Data Protection Act 2018. The redaction is also consistent with the Caldicott Principles.

I trust you will find the information of assistance and if you require any further information, please do not hesitate to contact us.

If you are unhappy with any aspect of how we have dealt with your request, you can make representations to us asking us to review the handling of your request.

If you require any further information, please contact the Associate Director Governance and Board Services (Board Secretary) within 40 working days of the date of this correspondence.

Contact

Email: nss.foi@nhs.scot

Address

NHS National Services Scotland
Headquarters
Gyle Square
1 South Gyle Crescent
Edinburgh
EH12 9EB

If after a review you are still unhappy, you also have the right to apply to the Scottish Information Commissioner, who can be contacted at Kinburn Castle, St Andrews, Fife, KY16 9DS, or via their application form.

National Services Scotland (NSS) is committed to publishing all information released in response to Freedom of Information requests. You can view all FOI responses within our FOI Publications repository.

Contents